Karin Weyer

7.3k citations

49 papers · 3.0k indexed · h-index 28

Impact in

Infectious Diseases top 0.5%
- Tuberculosis Research and Epidemiology
- HIV/AIDS drug development and treatment
Epidemiology top 1%
- Mycobacterium research and diagnosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumonia and Respiratory Infections

Papers in ⓘ

Infectious Diseases 45
- Tuberculosis Research and Epidemiology 44
- HIV/AIDS drug development and treatment 4
Epidemiology 33
- Mycobacterium research and diagnosis 19
- Pneumocystis jirovecii pneumonia detection and treatment 10
- Pneumonia and Respiratory Infections 9

Co-authors: Kayla F. Laserson (3 shared papers)Dennis Falzon (9 shared papers)Timothy H. Holtz (3 shared papers)Ernesto Jaramillo (7 shared papers)Charles D. Wells (2 shared papers)Katherine Floyd (5 shared papers)Alyssa Finlay (2 shared papers)Mario Raviǵlione (7 shared papers)
Journals: The Journal of Infectious Diseases (8 papers)European Respiratory Journal (4 papers)Tuberculosis (3 papers)Journal of Clinical Microbiology (3 papers)Bulletin of the World Health Organization (2 papers)
Partner nations: Switzerland United States South Africa

In The Last Decade

Karin Weyer

48 papers receiving 2.9k citations

Peers

Countries citing papers authored by Karin Weyer

Since Specialization

Citations

This map shows the geographic impact of Karin Weyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Weyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Weyer more than expected).

Fields of papers citing papers by Karin Weyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Weyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Weyer. The network helps show where Karin Weyer may publish in the future.

Co-authors

The 25 scholars most cited alongside Karin Weyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karin Weyer Line = papers co-authored together Karin Weyer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm The Journal of Infectious Diseases ·Charles D. Wells, J. Peter Cegielski, Lisa Nelson, Kayla F. Laserson, Timothy H. Holtz, Alyssa Finlay, Kenneth G. Castro, Karin Weyer	2007	371
2	World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update European Respiratory Journal ·Dennis Falzon, Holger J. Schünemann, Elizabeth Harausz, Licé González-Angulo, Christian Lienhardt, Ernesto Jaramillo, Karin Weyer	2017	263
3	Scaling up interventions to achieve global tuberculosis control: progress and new developments The Lancet ·Mario Raviǵlione, Ben J. Marais, Katherine Floyd, Knut Lönnroth, Haileyesus Getahun, Giovanni Battista Migliori, Anthony Harries, Paul Nunn, Christian Lienhardt, Stephen M. Graham, Jeremiah Chakaya, Karin Weyer, Stewart T. Cole, Stefan H. E. Kaufmann, Alimuddin Zumla	2012	248
4	Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. PubMed ·Kayla F. Laserson, Lorna E. Thorpe, Vaira Leimane, Karin Weyer, Carole D. Mitnick, Vija Riekstiņa, Evija Zarovska, Michael Rich, Hamish Fraser, E Alarcon, J. Peter Cegielski, M. Grzemska, Rajesh Gupta, Marcos Espinal	2005	233
5	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF European Respiratory Journal ·Karin Weyer, Fuad Mirzayev, Giovanni Battista Migliori, Wayne Van Gemert, Lia D’Ambrosio, Matteo Zignol, Katherine Floyd, Rosella Centis, Daniela María Cirillo, Enrico Tortoli, Chris Gilpin, Jean de Dieu Iragena, Dennis Falzon, Mario Raviǵlione	2012	167
6	Determinants of drug-resistant tuberculosis: analysis of 11 countries. PubMed ·Marcos Espinal, Kayla Laserson, M Camacho, Z Fusheng, S J Kim, R E Tlali, Ian M. Smith, Pedro Suarez, Mario Antunes, Abu George, N Martín-Casabona, P Simelane, Karin Weyer, Nancy Binkin, Mario Raviǵlione	2001	159
7	Defining the Needs for Next Generation Assays for Tuberculosis The Journal of Infectious Diseases ·Claudia M. Denkinger, Sandra V. Kik, Daniela María Cirillo, Martina Casenghi, Thomas M. Shinnick, Karin Weyer, Chris Gilpin, Catharina Boehme, Marco Schito, Michael Kimerling, Madhukar Pai	2015	113
8	Multidrug-resistant tuberculosis around the world: what progress has been made? European Respiratory Journal ·Dennis Falzon, Fuad Mirzayev, Fraser Wares, Inés García Baena, Matteo Zignol, Linh Nguyen, Karin Weyer, Ernesto Jaramillo, Katherine Floyd, Mario Raviǵlione	2014	102
9	Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa Antimicrobial Agents and Chemotherapy ·Walter Haas, K Schilke, Jeannette Brand, Beate Amthor, Karin Weyer, P. Bernard Fourie, Gisela Bretzel, V. Sticht-Groh, H. J. Bremer	1997	99
10	Pyrazinamide Resistance among South African Multidrug-Resistant Mycobacterium tuberculosis Isolates Journal of Clinical Microbiology ·Matsie Mphahlele, Heidi Syre, Håvard Valvatne, Ruth Stavrum, Turid Mannsåker, Tshilidzi Muthivhi, Karin Weyer, P. Bernard Fourie, Harleen M. S. Grewal	2008	95
11	Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence PLoS ONE ·Jason E. Farley, Malathi Ram, William Pan, Stacie Waldman, Gail H. Cassell, Richard E. Chaisson, Karin Weyer, Joey Lancaster, Martie van der Walt	2011	91
12	Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance New England Journal of Medicine ·Matteo Zignol, Anna Dean, Dennis Falzon, Wayne Van Gemert, A Wright, Armand Van Deun, Françoise Portaels, A László, Marcos Espinal, Ariel Pablos-Méndez, Amy Bloom, Mohamed A. Abd El Aziz, Karin Weyer, Ernesto Jaramillo, Paul Nunn, Katherine Floyd, Mario Raviǵlione	2016	90
13	Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. PubMed ·Timothy H. Holtz, J. Lancaster, Kayla F. Laserson, Charles D. Wells, Lorna E. Thorpe, Karin Weyer	2006	78
14	Institutional Tuberculosis Transmission. Controlled Trial of Upper Room Ultraviolet Air Disinfection: A Basis for New Dosing Guidelines American Journal of Respiratory and Critical Care Medicine ·Matsie Mphaphlele, Ashwin Dharmadhikari, Paul Jensen, Stephen N. Rudnick, Tobias H Van Reenen, Mario Pagano, Wilhelm Leuschner, Tim A. Sears, Sonya Milonova, Martie van der Walt, Anton Stoltz, Karin Weyer, Edward A. Nardell	2015	74
15	Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis European Respiratory Journal ·Andrea Pantoja, Christopher Fitzpatrick, Anna Vassall, Karin Weyer, Katherine Floyd	2012	72
16	Patient- and provider-level risk factors associated with default from tuberculosis treatment, South Africa, 2002: a case-control study BMC Public Health ·Alyssa Finlay, Joey Lancaster, Timothy H. Holtz, Karin Weyer, Abe Miranda, Martie van der Walt	2012	67
17	Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis Tuberculosis ·Ashwin Dharmadhikari, Randall J. Basaraba, Martie van der Walt, Karin Weyer, Matsie Mphahlele, Kobus Venter, Paul Jensen, M.W. First, Sydney Parsons, David N. McMurray, Ian M. Orme, Edward A. Nardell	2011	65
18	High Diversity ofMycobacterium tuberculosisGenotypes in South Africa and Preponderance of Mixed Infections among ST53 Isolates Journal of Clinical Microbiology ·Ruth Stavrum, Matsie Mphahlele, Kristi Øvreås, Tshilidzi Muthivhi, P. Bernard Fourie, Karin Weyer, Harleen M. S. Grewal	2009	61
19	Results of a tuberculosis-specific IFN-gamma assay in children at high risk for tuberculosis infection. PubMed ·Simon Tsiouris, Judith Austin, Patricia Lasso Toro, David Coetzee, Karin Weyer, Zena Stein, Wafaa El‐Sadr	2006	60
20	Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies BMJ Open ·Thomas J. Hwang, Svetlana Dotsenko, Alamdar Jafarov, Karin Weyer, Dennis Falzon, Kaspars Lunte, Paul Nunn, Ernesto Jaramillo, Salmaan Keshavjee, D. F. Wares	2014	57

About Karin Weyer

Karin Weyer is a scholar working on Infectious Diseases, Epidemiology, Geriatrics and Gerontology, Surgery and Endocrinology, having authored 49 papers that have together received 3.0k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (44 papers), Mycobacterium research and diagnosis (19 papers), Pneumocystis jirovecii pneumonia detection and treatment (10 papers), Diagnosis and treatment of tuberculosis (10 papers), Pneumonia and Respiratory Infections (9 papers), Infectious Diseases and Tuberculosis (7 papers), HIV/AIDS drug development and treatment (4 papers) and Biosimilars and Bioanalytical Methods (3 papers). The work is most often cited by research in Infectious Diseases (2.6k citations), Epidemiology (2.2k citations), Surgery (1.0k citations), Molecular Medicine (116 citations) and Applied Microbiology and Biotechnology (25 citations). Karin Weyer has collaborated with scholars based in Switzerland, United States and South Africa. Frequent co-authors include Kayla F. Laserson, Dennis Falzon, Timothy H. Holtz, Ernesto Jaramillo, Charles D. Wells, Katherine Floyd, Alyssa Finlay, Mario Raviǵlione, Christian Lienhardt and Kenneth G. Castro. Their work appears in journals such as The Journal of Infectious Diseases, European Respiratory Journal, Tuberculosis, Journal of Clinical Microbiology and Bulletin of the World Health Organization.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact